Stay updated with breaking news from Dose Reduction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The panel discusses the use of quality-of-life clinical trial data in metastatic renal cell carcinoma and how liver and brain metastases affect treatment decision-making.
Mehmet Asim Bilen, MD, details how he approaches IO/TKI therapy for patients with renal cell carcinoma with bone metastases.
Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.
Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.
/PRNewswire/ -- The "Pediatric Imaging Technology Innovation and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This study...